Our Management
Yusheng Han
Founder, Chairman of the Board of Directors and Chief Executive Officer
Mr. Yusheng Han is our founder, chairman of the board of directors and chief executive officer. Mr. Han has nearly 20 years of experience in life science. From June 2011 to November 2013, he was an associate in Northern Light Venture Capital where he focused on investment in the healthcare industry and helped the firm invest in successful companies. From July 2005 to May 2009, Mr. Han worked at BioTek Instruments, Inc. as its general manager in China. During his term with BioTek Instruments China, he built and led teams across marketing, sales and post-sale. From September 2003 to May 2005, he served as the product specialist of Gene Company Limited. Mr. Han received a bachelor's degree in biochemistry from Jilin University in July 2000, and a master's degree in cell biology in Peking Union Medical College in June 2003. He obtained a Master of Business Administration degree from Columbia Business School in May 2011.
Dr. Zhihong (Joe) Zhang
Director , Chief Technology Officer and General Manager
Dr. Zhihong (Joe) Zhang served as our chief technology officer since March 2016. Prior to joining us, Dr. Zhang was a staff scientist of Illumina, Inc., and a senior fellow of Howard Hughes Medical Institute and University of Washington. He obtained a bachelor's and master's degree in biochemistry and molecular biology from Fudan University in 1997 and 2000, and a Ph.D. degree in molecular genetics and microbiology from Duke University in 2005.
Dr. Xinru Mao
Vice President, Biomarker & CDx Service
Dr. Xinru Mao has over 16-year experiences of clinical R&D and a deep understanding of NGS-driven precision medicine, especially in oncology and CNS. Currently Dr. Mao is the Vice President of Biomarker & CDx Service in Burning Rock Dx (NASDAQ: BNR). She was also the medical director, responsible for regional medical affairs, and assembled the BNR’s first medical science liaison team. Before BNR, she worked in AstraZeneca clinical R&D department, and leaded several important registration clinical trials for drug R&D in China, including olaparib, osimertinib, Iressa, cediranib, etc.
